KPTI — Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. (KPTI) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $34.1 million, up 11.8% year-over-year.
• Full Year 2025 Revenue: $146.1 million, a slight increase from 2024.
• U.S. XPOVIO Net Product Revenue: $32.1 million in Q4 2025 (up 9.6% YoY) and $114.9 million for the full year (up 1.9% YoY).
• Gross-to-Net Provisions: 26.9% for Q4 and 31.2% for the full year.
• Operating Expenses: R&D expenses decreased by 17% to $27.7 million in Q4 and by 12% to $125.6 million for the full year. SG&A expenses also decreased by 16% in Q4 and 9% for the year.
• Net Loss: $102.2 million for Q4 and $196.0 million for the full year, primarily due to non-cash items like interest expense and loss on extinguishment of debt.
• Cash Position: Ended the year with $64.1 million in cash and equivalents, down from $109.1 million in 2024.

2. Strategic Updates and Business Highlights

• Clinical Trials: Karyopharm is focused on two pivotal Phase III trials: SENTRY for myelofibrosis (data expected in March 2026) and EXPORT EC042 for endometrial cancer (data expected mid-2026).
• Selinexor: The company is positioning selinexor as a combination therapy for myelofibrosis, aiming to improve patient outcomes compared to existing JAK inhibitors.
• Market Positioning: XPOVIO continues to show strong demand in the multiple myeloma market, with plans to expand into myelofibrosis and endometrial cancer.
• Commercial Strategy: Karyopharm is preparing for a rapid launch in myelofibrosis, targeting a significant unmet need in the market.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected total revenue of $130 million to $150 million, with U.S. XPOVIO net product revenue projected between $115 million and $130 million.
• Expense Guidance: R&D and SG&A expenses anticipated to be between $230 million and $245 million.
• Cash Runway: Current liquidity expected to fund operations into the second quarter of 2026.

4. Bad News, Challenges, or Points of Concern

• Net Loss: Significant net losses driven by non-cash items raise concerns about financial sustainability.
• Cash Decrease: The decline in cash reserves may limit operational flexibility and funding for ongoing trials.
• Competitive Pressures: The oncology market is highly competitive, particularly in myelofibrosis, where Karyopharm faces established therapies like ruxolitinib.
• Regulatory Uncertainty: While the company is optimistic about upcoming data readouts, the potential for regulatory hurdles remains a concern.

5. Notable Q&A Insights

• Efficacy of Selinexor: Management expressed confidence in the 60 mg dose of selinexor based on Phase I data, which showed better efficacy compared to the 40 mg dose.
• Symptomatic Improvement: KOL feedback suggests that while spleen volume reduction (SVR) is crucial, any significant improvement in symptoms could still support regulatory filing.
• Patient Population: The current trial population appears to be less severe than previous studies, but management believes this will not adversely affect efficacy outcomes.
• DSMB Oversight: The Data Safety Monitoring Board (DSMB) has not indicated any safety concerns, which supports confidence in the ongoing trials.

Overall, Karyopharm is navigating a critical phase with promising clinical data on the horizon, but faces financial challenges and competitive pressures that could impact its future trajectory.